Petros Pharma (NASDAQ:PTPI) Stock, Quote.Headers.trade-ideas

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

PTPI

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

Interview

General

Petros Pharmaceuticals specializes in men&#39;s health therapeutics. President Fady Boctor discusses the company&#39;s strategy to make key prescription medications. Petros is poised to expand within the $66.5 billion Rx-to-OTC market projected by 2033.

EXCLUSIVE: &#39;Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,&#39; Petros Pharma President Says

xr:d:DAFlNs0AWQM:2,j:6886396588877453870,t:23060806

Intraday Update

Markets

Movers

Trading Ideas

AMSC

AVGO

BITF

BMEA

BNED

BRTX

BURU

CARA

CERO

Core Scientific, Inc. - Class A Common Stock

CORZ

IONM

JILL

KYTX

LGVN

NWTN

PARA

PLAY

PRFX

RGEN

SPCE

STSS

SUPV

TELL

TSLA

VANI

WHLR

WLYB

ZAPP

Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

broadcom shutter3

Pre-Market Outlook

AEMD

EEIQ

MOLN

TCON

VIST

Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

Brazil's Supreme Court has fined Elon Musk&#8216;s social media platform nearly $1 million <a href="https://www.benzinga.com/news/24/09/40932378/elon-musks-x-manages-to-dodge-brazil-ban-with-software-update-court-wants-an-explanation">daily for allowing access to X, despite a ban</a>.
What Happened: The court accused Musk of switching X's network provider to partially restore access. This maneuver was seen as an attempt to bypass the ban imposed three weeks ago, <a href="https://www.wsj.com/world/americas/brazil-fines-musk-for-skirting-x-ban-945813ed">reported</a> The Wall Street Journal. 
In his latest ruling on Thursday, Justice Alexander de Moraes ordered X to immediately block user access to the platform in Brazil due to the network switch, or face a daily fine of approximately $921,000. The Brazilian judge described the crackdown on X as part of broader efforts to &#8220;clean up the internet.&#8221;
X stated it had no intention of evading the ban. The company claimed it was forced to switch providers after shutting down its Brazilian operations, which inadvertently restored service temporarily. However, de Moraes cited Musk's cryptic <a href="https://x.com/elonmusk/status/1836289127907758312">post</a> on X as a "confession" of deliberate circumvention.
De Moraes initially banned X on Aug. 30 for failing to block accounts spreading misinformation and hate speech. He emphasized the crackdown as part of efforts to "clean up the internet" and protect democracy, following violent attacks on Brazil's capital last year.
Brazil's telecom regulator, Anatel, accused Musk of intentionally defying the court order. They are working with Cloudflare to find a solution to enforce the ban without disrupting other services, according to the report.
See Also: <a href="https://www.benzinga.com/news/24/09/40897703/former-tesla-exec-says-elon-musks-endorsement-of-trump-might-not-sway-upcoming-presidential-election?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Former Tesla Exec Says Elon Musk&#8217;s Endorsement Of Trump Might Not Sway Upcoming Presidential Elections: &#8216;Last Time Around He Endorsed Andrew Yang&#8217;</a>
Why It Matters: The conflict between Musk and Brazil&#8217;s government has broader implications. On Thursday, the Brazilian Association of Internet and Telecommunications Providers reported that <a href="https://www.benzinga.com/news/24/09/40932378/elon-musks-x-manages-to-dodge-brazil-ban-with-software-update-court-wants-an-explanation">X managed to dodge the ban</a> using an automatic software update, complicating efforts to block the platform. This maneuver has raised questions about the effectiveness of Brazil&#8217;s regulatory measures.
Earlier in the month, FCC Commissioner Brendan Carr <a href="https://www.benzinga.com/news/24/09/40748476/fcc-chief-defends-elon-musks-x-and-starlink-amid-brazils-punitive-actions-warns-business-leaders-are">criticized Brazil&#8217;s actions</a>, warning that such punitive measures could make Brazil an &#8220;uninvestable market.&#8221; Carr&#8217;s comments reflect growing concerns among U.S. business leaders about the stability of Brazil&#8217;s regulatory environment.
The situation has also affected Musk&#8217;s other ventures. On Sept. 5, SpaceX <a href="https://www.benzinga.com/news/24/09/40723859/spacex-reportedly-evacuates-employees-from-brazil-halts-travel-amid-elon-musks-legal-battle-with-sup">evacuated employees from Brazil </a>and halted travel to the country amid the legal battle. This move underscores the broader impact of the dispute on Musk&#8217;s business operations.
Moreover, experts warned that the standoff could affect other Musk ventures like SpaceX and Tesla Inc. Tim Higgins noted that the ban on X could <a href="https://www.benzinga.com/news/24/09/40709109/elon-musks-brazil-standoff-for-x-could-impact-tesla-spacex-and-other-ventures-warns-expert">jeopardize Musk&#8217;s business opportunities in Brazil</a>, particularly in rural areas where his ventures have been successful.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40893054/mark-cuban-says-he-would-buy-rupert-murdochs-fox-news-and-elon-musks-x-but-there-are-some-obstacles?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says He Would Buy Rupert Murdoch&#8217;s Fox News And Elon Musk&#8217;s X But There Are Some Obstacles: &#8216;If I Had Enough… I&#8217;d Buy It In A Heartbeat&#8217;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Social Media

Legal

Global

Elon Musk's X Fined $1M A Day By Brazil's Supreme Court For Defying Ban On Platform: Judge Says Part Of Effort To 'Clean Up The Internet'

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jones index and S&amp;P 500 hitting fresh record highs during the session. The US Federal Reserve, on Wednesday, slashed interest rates by 50 basis points Wednesday at its September Federal Open Market Committee meeting, lowering the federal funds rate to a range of 4.75% to 5%.
On the economic data front, the U.S. reported a current account deficit of $266.8 billion in the second quarter versus a gap of $241 billion in the prior period and higher than market estimates of a $260 billion gap. U.S. initial jobless claims fell by 12,000 from the prior week to 219,000 in the week ending September 14, compared to market expectations of 230,000.
Tech stocks rallied, with shares of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) gaining around 4% and 6%, respectively. Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares added 2.2% during the session. Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) also surged, closing the day with gains of 7.4%.
Most sectors on the S&amp;P 500 closed on a positive note, with consumer discretionary, communication services, and information technology stocks recording the biggest gains on Thursday. However, consumer staples and utilities stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 522 points to 42,025.19 on Thursday. The S&amp;P 500 surged 1.70% to 5,713.64, while the Nasdaq Composite climbed 2.51% at 18,013.98 during Thursday's session.
Investors are awaiting earnings results from VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 65.7, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 60.8.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40948972/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>

Earnings

NVDA

Nvidia, Tesla Rally As Dow, S&P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In 'Greed' Zone

General Motors' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) autonomous driving unit Cruise said on Thursday that it is eyeing resuming operations of its robotaxis in California which was paused after the involvement of one of its driverless vehicles in a <a href="https://www.benzinga.com/markets/equities/23/12/36246017/future-of-gm-autonomous-vehicle-maker-cruise-in-peril-after-900-job-cuts">pedestrian accident</a> late last year.
What Happened: The company said that it will deploy several manual mapping vehicles in Sunnyvale and Mountain View starting Thursday. The company intends to start supervised robotaxi testing in the state later this fall with up to five autonomous vehicles, it added.
&#8220;Resuming testing in the Bay Area is an important step forward as we continue to work closely with California regulators and local stakeholders. This will allow our local employees to engage directly with our product as they refine and improve our tech through R&amp;D,&#8221; the company said in a post on social media platform X, formerly Twitter.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Starting today we will deploy several manual mapping vehicles in Sunnyvale and Mountain View with the intent to progress to supervised testing with up to 5 AVs later this fall. Resuming testing in the Bay Area is an important step forward as we continue to work closely with… <a href="https://t.co/OlDkv74r34">pic.twitter.com/OlDkv74r34</a>
&mdash; cruise (@Cruise) <a href="https://twitter.com/Cruise/status/1836812363963486286?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Cruise suspended all of its operations in the U.S. late last year following the involvement of one of its robotaxis in an accident in San Francisco, leading to heightened regulatory scrutiny and the <a href="https://www.benzinga.com/news/24/05/38606510/us-is-currently-sc-ed-ex-cruise-ceo-calls-for-manufacturing-makeover-to-win-over-chinese-auto-rivals" target="_blank" rel="noreferrer noopener">exit of its co-founder </a>and then CEO Kyle Vogt.
The company&nbsp;<a href="https://www.benzinga.com/news/24/04/38155753/cruise-back-on-phoenix-roads-soon-gms-self-driving-unit-reportedly-gears-up-to-resume-robotaxi-testi" target="_blank" rel="noreferrer noopener">resumed manual driving in the city of Phoenix</a>&nbsp;to gather road information earlier this year in April and in Houston and Dallas, Texas in June.
For the first half of 2024, Cruise accrued an operating loss of $1.65 billion, 28% higher than the loss of $1.29 billion recorded in the corresponding period of last year. GM also spent $583 million on restructuring Cruise in the period.
Last month, Cruise issued a <a href="https://www.benzinga.com/news/24/08/40502871/gms-autonomous-driving-unit-cruise-recalls-all-u-s-vehicles-over-concerns-of-unexpected-braking-auto">recall for the entirety of its U.S. fleet</a> over concerns that they may brake unexpectedly. The company updated software in all of its vehicles on the road to fix the issue. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40934031/teamsters-opts-to-not-endorse-either-harris-or-trump-for-upcoming-presidential-elections-citing-fail" target="_blank" rel="noreferrer noopener">Teamsters Opts To Not Endorse Either Harris Or Trump For Upcoming Presidential Elections, Citing Failure To Secure Pledges Of Non-Interference In Union Campaigns</a></li>
</ul>
Photo via Shutterstock

Tech

GM's Cruise Eyes Resuming Robotaxi Operations In California After Long Pause Due To Pedestrian Accident In 2023

The United States will continue to keep a mid-range missile system in the Philippines, the decision comes despite demands from <a href="https://www.benzinga.com/news/24/07/39710570/us-has-better-global-image-than-china-survey-reveals">China for its removal</a>.
What Happened: The Typhon missile system, capable of launching missiles that can reach Chinese targets, was initially deployed for joint exercises earlier this year. However, it has remained in place, reported Reuters on Friday, citing sources familiar with the situation.
The Philippines, located near Taiwan, is a crucial part of the U.S. strategy in Asia. The missile system&#8217;s presence is seen as vital for supporting Taiwan in the event of a Chinese attack.
China and Russia have criticized the deployment, accusing the U.S. of escalating an arms race. China&#8217;s foreign ministry expressed significant concern over the decision to keep the system in place, stating it threatens regional security.
Philippine officials confirmed ongoing training with the missile system on the northern island of Luzon, near the South China Sea and Taiwan Strait, according to the report. They indicated no immediate plans to withdraw the system, even though joint exercises conclude this month.
A senior Philippine government official noted that the U.S. and the Philippines are testing the system&#8217;s feasibility for potential conflict scenarios. 
&#8220;It is up to the higher headquarters to decide on its stay, and most importantly the United States Army Pacific&nbsp;(USARPAC) because they own this, it is not our capability,&#8221; Philippines army spokesman, Colonel Louie Dema-ala said according to the report.
See Also: <a href="https://www.benzinga.com/news/24/09/40935722/spacex-ceo-elon-musk-says-anyone-can-go-to-mars-with-spacex-but-journey-would-be-like-a-long-sea-voy?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">SpaceX CEO Elon Musk Says Anyone Can Go To Mars With SpaceX But Journey Would Be Like A &#8216;Long Sea Voyage In Centuries Past&#8217;</a>
Why It Matters: The decision to retain the missile system in the Philippines comes amid a series of escalating tensions between the U.S. and China. 
Recently, President Joe Biden&#8216;s administration launched an investigation into a significant rise in <a href="https://www.benzinga.com/news/24/09/40896792/us-probes-surge-in-chinese-uranium-imports-amid-fears-of-russian-ban-evasion">enriched uranium imports from China</a>, suspecting it as a potential loophole for Russia to bypass a U.S. import ban. 
Additionally, key congressional panels have warned that the U.S. is lagging behind China in war preparedness. Lawmakers have <a href="https://www.benzinga.com/news/24/09/40936105/us-lagging-behind-china-in-war-preparedness-congressional-panels-warn">criticized outdated Pentagon procedures</a> and emphasized the need for faster technology transfers to allies.
Tensions in the South China Sea have also been on the rise. In June, a collision between Chinese and Philippine vessels near the Spratly Islands led to accusations of <a href="https://www.benzinga.com/news/24/06/39351335/us-ally-slams-chinas-claims-of-vessel-collision-as-deceptive-and-misleading-amid-rising-south-china">deceptive information from Beijing</a>. The Philippine military has previously condemned China&#8217;s actions as illegal within their exclusive economic zone.
Furthermore, a survey by the Pew Research Center revealed that the U.S. enjoys a significantly <a href="https://www.benzinga.com/news/24/07/39710570/us-has-better-global-image-than-china-survey-reveals">better global image</a> than China in numerous high- and middle-income countries. This perception plays a crucial role in the ongoing geopolitical rivalry between the two nations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40931458/obama-era-economist-says-she-is-pleasantly-surprised-that-jd-vance-thinks-the-economy-is-too-strong?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Obama-Era Economist Says She Is &#8216;Pleasantly Surprised&#8217; That JD Vance Thinks The &#8216;Economy Is Too Strong For The Rate Cut&#8217;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

US Keeps Missiles Vital For Defence Of Taiwan In Philippines Despite Beijing's Demands For Removal: Report

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>FedEx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) reported <a href="https://www.benzinga.com/news/earnings/24/09/40948046/fedex-q1-earnings-revenue-miss-eps-miss-lowered-guidance-challenging-quarter">weaker-than-expected results</a> for the first quarter of fiscal 2025 and lowered its full-year guidance. The company reported first-quarter revenue of $21.6 billion, missing analyst estimates of $21.955 billion, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company reported first-quarter adjusted earnings of $3.60 per share, missing analyst estimates of $4.80 per share. FedEx shares tumbled 11% to $267.25 in the after-hours trading session.</li>
<li>Wall Street expects VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) to report a quarterly loss at 21 cents per share on revenue of $460.09 million before the opening bell. VinFast Auto shares rose 0.2% to $3.9665 in after-hours trading.</li>
<li>Chewy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) announced a public offering by a selling stockholder and a concurrent share repurchase. Chewy shares fell 0.8% to $30.85 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>MillerKnoll, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) reported downbeat <a href="https://www.benzinga.com/news/earnings/24/09/40949071/millerknoll-stock-dips-after-q1-results-heres-why">first-quarter financial results</a> on Thursday. The company also said it sees second-quarter earnings of between 51 cents and 57 cents per share, versus the estimate of 61 cents, and second-quarter revenue in a range of $950 million to $990 million, versus the $948.12 million estimate. MillerKnoll shares declined 5.3% to $26.02 in the after-hours trading session.</li>
<li>Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) <a href="https://www.benzinga.com/news/earnings/24/09/40948948/homebuilder-lennar-reports-better-than-expected-q3-results-details">reported</a> better-than-expected financial results for the third quarter. The company said it sees fourth-quarter new orders in a range of 19,000 to 19,300 and deliveries between 22,500 and 23,000. The company expects the average sales price to be approximately $425,000. Lennar shares fell 2.4% to $187.75 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40948972/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>
Photo courtesy: Shutterstock

CHWY

MLKN

FedEx, Lennar And 3 Stocks To Watch Heading Into Friday

Palantir Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) co-founder, Joe Lonsdale, has expressed his support for Tesla and SpaceX CEO Elon Musk&#8217;s <a href="https://www.benzinga.com/news/23/04/31810229/elon-musk-bought-twitter-1-year-ago-a-look-back-at-whats-happened-since-and-what-could-be-next">acquisition of</a> Twitter, now rebranded as X.
What Happened: On Thursday, while appearing on CNBC&#8217;s Squawk Box, Lonsdale was asked about Musk&#8217;s sentiments toward his $44 billion purchase of Twitter. 
Lonsdale responded positively, suggesting that Musk&#8217;s acquisition was a crucial step for the preservation of the West.
&#8220;If Elon hadn&#8217;t bought Twitter, if he hadn&#8217;t done this, the entire West would be at 10x the threat,&#8221; he said and went on to underscore the significance of free speech in maintaining our civilization.
See Also: <a href="https://www.benzinga.com/news/23/05/32623067/how-to-take-the-perfect-moon-shot-using-an-iphone-14?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Take The Perfect Moon Shot Using An iPhone 15</a>
When probed about the financial implications of the acquisition, Lonsdale acknowledged a decrease in revenue due to brands pulling their support.
However, he contended that this was a result of illegal coordination and attacks, which he deemed &#8220;probably illegal.&#8221;
he stated that while brands have the right to withdraw their support, behind-the-scenes coordination to damage a company is inappropriate.
Musk also shared the clip from this discussion on X and said, &#8220;Thanks Joe.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thanks Joe <a href="https://t.co/swbYEjVnGW">https://t.co/swbYEjVnGW</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1836806074638434556?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Musk&#8217;s acquisition of Twitter has been fraught with controversy. Just earlier this month, it was reported that X is expected to see a drastic <a href="https://www.benzinga.com/news/24/09/40762349/x-faces-major-advertiser-exodus-amid-string-of-elon-musk-controversies">reduction in advertising expenditure</a> in 2025, following a 26% decline in marketers' ad spending on the platform.
Last month, it was reported that since Musk&#8217;s acquisition, <a href="https://www.benzinga.com/startups/24/08/40533138/as-twitters-revenue-collapses-by-84-tesla-bulls-fear-elon-musk-will-liquidate-more-tesla-stock-bring">X&#8217;s revenue has plummeted by 84%</a>. This number also reportedly sparked fears among Tesla investors that Musk might sell more of his Tesla stock to fill the financial gap.
Previously, Meta Platforms Inc's president for global affairs, Nick Clegg, also criticized X for becoming a "tiny" platform for elites that <a href="https://www.benzinga.com/news/24/09/40852207/meta-exec-slams-elon-musks-x-as-tiny-platform-that-allows-anyone-say-anything">permits anyone to say anything</a>.
He also noted that individuals banned from Meta's platforms like Facebook and Instagram remain active on X and Telegram, and were involved in the far-right protests and riots in Britain last month.
Meanwhile, on Thursday morning, Palantir <a href="https://www.benzinga.com/news/24/09/40939510/palantir-stock-hits-52-week-highs-thursday-whats-going-on">shares made a new 52-week high</a>. This development came after the company got a new contract from the U.S. Army worth $99.8 million.
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40914747/jpmorgan-ceo-jamie-dimon-thinks-social-media-platforms-like-tiktok-and-facebook-are-a-total-stupid-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">JPMorgan CEO Jamie Dimon Thinks Social Media Platforms Like TikTok And Facebook Are &#8216;A Total Stupid Waste Of Time&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

PLTR

Palantir Co-Founder Joe Lonsdale Backs Elon Musk's Twitter Acquisition, Saying If He Had Not Bought It Then 'The Entire West Would Be At 10x The Threat'

<ul>
<li>Kineta will be trading under the symbol &quot;KANT&quot; on OTC Pink</li>
<li>Kineta will continue to pursue strategic alternatives as previously announced</li>
<li>TuHURA Biosciences has an exclusivity right and a right of first offer for Kineta&#39;s KVA12123 program</li>
<li>The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patients previously enrolled.</li>
</ul>

Reported Earlier, Kineta Transitions From Nasdaq To OTC Markets, Continues Focus On Strategic Alternatives

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking&nbsp;the third new indication for RYBREVANT&reg;&nbsp;this year, with four indications overall

Johnson & Johnson Announces FDA Approval Of RYBREVANT Plus Chemotherapy As The First Targeted Therapy To Halve Disease Progression Risk In Second-Line EGFR-Mutated Lung Cancer

Macro Economic Events

Econ #s

Economics

Germany Producer Price Index (MoM) For August 0.2% Vs. 0.0% Est.; 0.2% Prior

U.K. Retail Sales (YoY) For August 2.5% Vs. 1.4% Est.; 1.5% (Revised) Prior

U.K. Retail Sales (MoM) For August 1.0% Vs. 0.3% Est.; 0.7% (Revised) Prior

U.K. Core Retail Sales (YoY) For August 2.3% Vs. 1.1% Est.; 1.4% Prior

U.K. Core Retail Sales (MoM) For August 1.1% Vs. 0.5% Est.; 1.0% (Revised) Prior

TRIN

Reported Earlier, Trinity Capital Expands Credit Facility To $510M With $70M Boost From New Lenders

Ascendis estimates the net proceeds from the offering will be approximately&nbsp;$281.3 million&nbsp;(assuming no exercise of the underwriters&#39; option to purchase additional ADSs), after deducting the underwriting commissions and estimated offering expenses. Ascendis intends to use the net proceeds of the offering to support the commercial preparations, launch and commercial activities, clinical development and regulatory approvals for its products and product candidates, and for working capital and general corporate purposes.

ASND

Reported Earlier, Ascendis Pharma Prices $281.3M Public Offering Of 2M ADSs At $150/ADS

Leveraging NVIDIA accelerated computing and offering personalized drinks, Scorpion is expected to save costs, generate revenue, and provide an unforgettable customer experience

Reported Earlier, Richtech Robotics Launches Scorpion, An AI-Driven Single-Arm Beverage Service Robot, And Secures 500-Unit Distribution Deal Over Five Years

Agreement designed to foster collaboration and usage of quantum computing solutions for optimization and AI applications

QBTS

Reported Earlier, D-Wave And Staque Join Forces To Accelerate Annealing Quantum Computing Adoption Across The Middle East

The gross proceeds from the sale of the shares by the Selling Stockholders will be approximately $2.2 billion. Diamondback will not receive any proceeds from the sale of the shares by the Selling Stockholders. The Secondary Offering is expected to close on September 23, 2024, subject to customary closing conditions.
In addition, Diamondback has agreed to purchase from the underwriters 2,000,000 shares of common stock that are the subject of the Secondary Offering at a price per share equal to the price per share to be paid by the underwriters to the Selling Stockholders (the &quot;Share Repurchase&quot;) under Diamondback&#39;s existing share repurchase program. Diamondback plans to fund the Share Repurchase from existing cash on hand. The underwriters will not receive any compensation for the shares being repurchased by Diamondback in the Share Repurchase.

FANG

Reported Earlier, Diamondback Energy Prices Upsized $2.2B Secondary Common Stock Offering Of 12.77M Shares

YouTube, a subsidiary of&nbsp;Alphabet Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, has announced the implementation of &#8220;Pause ads,&#8221; a feature that <a href="https://www.benzinga.com/news/23/11/35613857/youtubes-war-against-ad-blockers-leads-to-record-uninstalls-but-users-are-fighting-back">displays advertisements</a> even when a video is paused.
What Happened: On Thursday, YouTube confirmed the broad rollout of &#8220;Pause ads&#8221; to all advertisers. Now, when a user pauses a video, an ad will appear&nbsp;on the side of the&nbsp;screen, <a href="https://edition.cnn.com/2024/09/19/business/youtube-ads-paused-screen/index.html">reported</a> CNN.
The new feature is intended to be &#8220;seamless for viewers&#8221; and offers an opportunity for&nbsp;them to learn more about&nbsp;a brand, a Google spokesperson told the report.
The update is seen as beneficial&nbsp;for the entire YouTube ecosystem&nbsp;and is part of the modern Connected TV (CTV) ads experience.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/40932378/elon-musks-x-manages-to-dodge-brazil-ban-with-software-update-court-wants-an-explanation?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s X Manages To Dodge Brazil Ban With Software Update, Court Wants An Explanation</a>
Despite YouTube&#8217;s assertion that&nbsp;the update creates a less&nbsp;interruptive viewing experience, social media users have voiced their annoyance over the new, unavoidable ads.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Seriously <a href="https://twitter.com/YouTube?ref_src=twsrc%5Etfw">@YouTube</a>? You&#39;re putting up ads when you pause a video now? I am about to install a computer in place of the fire stick so I can have an ad blocker&#8230; Your ads are getting ridiculous. <a href="https://t.co/OT4JMduGTU">pic.twitter.com/OT4JMduGTU</a>
&mdash; RoÆther (@Roaether) <a href="https://twitter.com/Roaether/status/1832186161743216724?ref_src=twsrc%5Etfw">September 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">nice one thing i hate when i pause a youtube video is the silence <a href="https://t.co/86sNagJ9Y4">https://t.co/86sNagJ9Y4</a>
&mdash; Keefler (@Keefler_Elf) <a href="https://twitter.com/Keefler_Elf/status/1836947769317020159?ref_src=twsrc%5Etfw">September 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/YouTube?ref_src=twsrc%5Etfw">@YouTube</a> Playing ads when pausing a video is an absolute trash idea. Stop trying these atrocious implementations to try to strongarm users into your subscription service. When I pause a video I want to disconnect not have to also wait to mute/pause/skip and ad.
&mdash; Cannoli Senpai (@CannoliSenpai) <a href="https://twitter.com/CannoliSenpai/status/1836956020226040198?ref_src=twsrc%5Etfw">September 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Users can still avoid ads&nbsp;with a YouTube Premium subscription, which costs&nbsp;$13.99 a month for an&nbsp;individual.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The introduction of &#8216;Pause ads&#8217; comes amid growing user frustration over the increasing number of ads on YouTube. Last year, Elon Musk agreed with millions of users worldwide that <a href="https://www.benzinga.com/news/23/10/35483941/elon-musk-agrees-with-millions-of-users-worldwide-youtube-ads-are-getting-out-of-control">YouTube ads were &#8220;getting out of control.&#8221;</a>
In May this year, some YouTube users with ad blockers installed reported that their videos were skipping to the end, a phenomenon that was speculated to be a strategy by <a href="https://www.benzinga.com/news/24/05/39054233/youtube-videos-reportedly-skipping-to-the-end-for-ad-block-users-bug-or-strategy">YouTube to counter ad blockers</a>.
YouTube has also been experimenting with new ways to prevent rampant ad-blocking on the platform, including <a href="https://www.benzinga.com/general/entertainment/24/06/39438445/youtube-steps-up-ad-blocker-crackdown-is-it-making-a-difference">server-side ad injection</a>.
Image via Shutterstock
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40892284/oracles-larry-ellison-predicts-police-officers-will-be-supervised-at-all-times-and-citizens-will-be?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Oracle&#8217;s Larry Ellison Predicts Police Officers Will Be Supervised &#8216;At All Times&#8217; And Citizens Will Be On Their Best Behavior Thanks To Constant AI-Powered Surveillance</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Media

GOOG

GOOGL

There Is No Escaping YouTube Ads Even After Hitting The Pause Button — Disgruntled Users Cry Foul: 'An Absolute Trash Idea'

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan Interest Rate Decision Unchanged At 0.25%

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Petros Pharmaceuticals (PTPI – Research Report), with a pric...

Positive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra Developments

Petros Pharmaceuticals files $100M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the first quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -$1.69. This was below the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $1.39 million.</li><li>This was 4.21% worse than the analyst estimate for revenue of $1.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ptpi-stock-earnings-petros-pharmaceuticals-for-q1-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024

Analyst Naz Rahman from Maxim Group maintained a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and keeping the price target at $4.0...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Strategic Shift to OTC Market and Positive Regulatory Prospects

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the second quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

ROMA

SIFYR

SQNS

VSME

XPON

Contracts

Press Releases

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Petros Pharma

Petros Pharma (PTPI) Forecast

Petros Pharma (NASDAQ:PTPI) Stock, Quote.Headers.trade-ideas